Publication details
Studie GALACTIC‑HF
| Title in English | Studie GALACTIC-HF |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| web | http://www.remedia.cz/Archiv-rocniku/Rocnik-2021/2-2021/e-33h-37m.magissue.aspx?Page=2 |
| Keywords | heart failure; omecamtiv mecarbil; reduced left ventricular ejection fraction |
| Description | Omecamtiv mecarbil represents cardiac-specific activator of myosin. In the GALACTIC-HF study, this medicinal product statistically significantly reduced the risk of primary composite endpoint (first occurrence of heart failure – hospitalization or urgent visit for heart failure – or cardiovascular death) in patients with heart failure and reduced left ventricular ejection fraction. |